Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving Average – Should You Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $9.90 and traded as low as $7.10. Arcturus Therapeutics shares last traded at $7.72, with a volume of 907,435 shares traded.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ARCT. B. Riley Financial assumed coverage on shares of Arcturus Therapeutics in a report on Wednesday, March 18th. They issued a “buy” rating and a $22.00 target price for the company. Roth Mkm initiated coverage on Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Piper Sandler reduced their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Arcturus Therapeutics Trading Up 11.9%

The stock has a market capitalization of $219.43 million, a PE ratio of -3.24 and a beta of 2.40. The stock’s fifty day simple moving average is $7.36 and its 200-day simple moving average is $9.90.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The firm had revenue of $7.20 million during the quarter, compared to analysts’ expectations of $14.32 million. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. As a group, analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC grew its holdings in Arcturus Therapeutics by 9.2% during the third quarter. ARK Investment Management LLC now owns 1,872,721 shares of the biotechnology company’s stock valued at $34,514,000 after purchasing an additional 157,681 shares during the period. Amova Asset Management Americas Inc. increased its position in shares of Arcturus Therapeutics by 6.4% during the third quarter. Amova Asset Management Americas Inc. now owns 1,947,835 shares of the biotechnology company’s stock valued at $35,879,000 after buying an additional 117,632 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Arcturus Therapeutics by 6.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,947,835 shares of the biotechnology company’s stock valued at $35,899,000 after purchasing an additional 115,368 shares during the period. BNP Paribas Financial Markets grew its position in Arcturus Therapeutics by 64.3% during the third quarter. BNP Paribas Financial Markets now owns 6,848 shares of the biotechnology company’s stock worth $126,000 after buying an additional 2,679 shares in the last quarter. Finally, Aristides Capital LLC bought a new position in shares of Arcturus Therapeutics in the fourth quarter worth approximately $161,000. 94.54% of the stock is owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.